Trial Profile

Phase 3 trial of EDP1815 in influenza

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EDP-1815 (Primary)
Indications Influenza virus infections
Focus Registrational; Therapeutic Use
Sponsors Evelo Biosciences

Most Recent Events

14 May 2020 New trial record
11 May 2020 According to an Evelo Biosciences media release, if the Phase 2 trial is successful in COVID-19, it plans to move into Phase 3, with the goal of advancing EDP1815 towards potential registration, and to investigate EDP1815 as a potential therapy for other diseases such as influenza.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com